Mice of the ddY strain began to receive Erythromycin dihyrate 7 days after inoculation of EAC cells, and CDF mice begins to receive Erythromycin dihyrate immediately after inoculation of P388 cells. Erythromycin dihyrate (gastric intubation; 0.1-50 mg/ kg; 30-120 days) decreases tumor growth from the dose of 5 mg/kg, mice receiving 1-10 mg/kg of Erythromycin dihyrate survives much longer than control mice, Only 10% of mice treated with 5 mg/kg of Erythromycin dihyrate had no evidence of tumor formation on day 60, and the mice are alive even at 120 days after inoculation. However, treatment with 50 mg/kg of Erythromycin dihyrate shortens mean survival time in tumorbearing mice by 4-5 days when it compares to controls.
| Animal Model: | Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 ce lls |
| Dosage: | 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg |
| Administration: | Gastric intubation; 30-120 days |
| Result: | Decrease tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortens the MST in tumorbearing mice. |
